CANbridge is actively seeking partnerships with global bio-pharmaceutical companies and academic institutions.We are focusing on opportunities in following areas
In-licensing or co-development of clinical-stage product candidates on indications highly relevant to Chinese and Asians.
Commercialization of orphan and other specialty products in China, Taiwan and Korea.
CANbridge has entered into multiple types of strategic partnership arrangements with several leading pharmaceutical and biotech companies.
In May 2017, CANbridge entered into a strategic partnership with Amoy Diagnostics to develop a companion diagnostic assay for CANbridge’s lead candidate, CAN008, a fully human Fc fusion protein. Previous clinical work, in a Phase II trial conducted in Europe, demonstrated a significant overall survival benefit for recurrent glioblastoma multiforme (GBM) patients with high expression of the CD95 ligand, or low methylation of CD95L promotor, CpG2.
In March 2016, CANbridge entered into an exclusive collaboration and license agreement with AVEO, in which AVEO has
granted CANbridge worldwide rights, excluding the United States, Canada, and Mexico, to AV-203, AVEO's clinical-stage
ErbB3 (HER3) inhibitory antibody candidate.
Under the terms of the agreement, CANbridge Life Sciences is obligated to pay AVEO an upfront payment of $1 million plus up to $133 million in potential reimbursement and milestone payments, assuming the successful achievement of specified development, regulatory and commercialization objectives. AVEO is also eligible for a tiered royalty, with a percentage range in the low double digits, on net sales of AV-203 in the agreement's territories.
In July 2015, CANbridge entered into an exclusive license agreement with privately-held immuno-oncology company, Apogenix to develop, manufacture and commercialize Apogenix's lead product, APG101 in glioblastoma multiforme in China, Macao, Hong Kong and Taiwan, with options for other indications.
Under the terms of the agreement, Apogenix will receive upfront and milestone payments, as well as royalty payments, at tiered, double-digit royalty rates following commercial launch of APG101 in China.
In Aug 2016, CANbridge entered into strategic partnership with Boehringer Ingelheim for the manufacture of CAN017, an ErbB3 (HER3) inhibitory antibody to treat esophageal squamous cell cancer (ESCC). Boehringer Ingelheim is a leading player in developing and manufacturing biopharmaceuticals, with world-class bioprocess capabilities, BI help CANbridge step up efforts to bring innovative bio-medicines to the market and benefit patients quickly.
In July 2014, CANbridge entered into an exclusive partnership with EUSA Pharma, a Jazz Pharmaceuticals company (Nasdaq: JAZZ), to commercialize Caphosol® in China. Under the terms of the agreement, CANbridge obtains exclusive rights to commercialize Caphosol in China, where over 3.5 million new cancer cases are diagnosed each year, and there is little in the way of a standard adjunct therapy to treat oral mucositis.
Established in December 2000, WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services throughout the drug R&D process.